Quality of life · patients with schizophrenia
1 finding from 1 review
Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Adverse effects: Clinically important general adverse effect (EPSEs requiring medication ‐ medium term) · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect (EPSEs… compared with perphenazine (very low certainty).
1 finding from 1 review
Death: Suicide and natural causes (no data) · schizophrenia
1 finding from 1 review
Length of hospital stay · schizophrenia
1 finding from 1 review
Mental state: Average endpoint general mental state score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason, short and medium term) compared with perphenazine (very low certainty).
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for rapid tranquillisation ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ injury or threat of self to others ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome: general ‐ no improvement · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome: general ‐ no improvement compared with OTHER ANTIPSYCHOTIC: f. PERPHENAZINE (very low certainty).
1 finding from 1 review
Adverse effect: Specific ‐ hypotensive episode · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effect: Specific ‐ hypotensive episode compared with OTHER ANTIPSYCHOTIC: f. PERPHENAZINE (very low certainty).
1 finding from 1 review
Adverse effect ‐ discontinued due to EPS · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effect ‐ discontinued due to EPS compared with OTHER ANTIPSYCHOTIC: f. PERPHENAZINE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found